This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Heresco-Levy, U.
Right arrow Articles by Kelly, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heresco-Levy, U.
Right arrow Articles by Kelly, D.

The British Journal of Psychiatry 169: 610-617 (1996)
© 1996 The Royal College of Psychiatrists

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

U Heresco-Levy, DC Javitt, M Ermilov, C Mordel, A Horowitz and D Kelly
Ezrath Nashim-Herzog Memorial Hospital, Hadassah Medical School-Hebrew University, Jerusalem, Israel.

BACKGROUND: It has been proposed that schizophrenia is associated with underactivity of brain glutamatergic neurotransmission, especially at the level of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Glycine potentiates NMDA receptor-mediated neurotransmission, indicating that it may serve as an effective therapeutic agent in the treatment of schizophrenia. METHOD: Eleven treatment-resistant patients with chronic schizophrenia completed a double-blind, placebo- controlled, six-week, randomly assigned, crossover treatment trial of 0.8 g/kg body weight/day of glycine, added to their prior antipsychotic treatment. RESULTS: Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0.0001). Significant improvements were also induced in depressive and cognitive symptoms. The greatest reduction in negative symptoms was registered in the patients who had the lowest baseline serum glycine levels. CONCLUSIONS: These results extend previous findings and suggest an additional approach to the pharmacotherapy of negative symptoms and cognitive deficits in schizophrenia.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. M. Smith, J. M. Uslaner, L. Yao, C. M. Mullins, N. O. Surles, S. L. Huszar, C. H. McNaughton, D. M. Pascarella, M. Kandebo, R. M. Hinchliffe, et al.
The Behavioral and Neurochemical Effects of a Novel D-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and D-Serine
J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 921 - 930.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. E. Tsai, H.-Y. Lane, C. M. VanDenBerg, Y.-C. Liu, P. Tsai, and M. W. Jann
Disposition of D-Serine in Healthy Adults
J. Clin. Pharmacol., April 1, 2008; 48(4): 524 - 527.
[Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. W. Buchanan, D. C. Javitt, S. R. Marder, N. R. Schooler, J. M. Gold, R. P. McMahon, U. Heresco-Levy, and W. T. Carpenter
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments
Am J Psychiatry, October 1, 2007; 164(10): 1593 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
S. M Erhart, S. R Marder, and W. T Carpenter
Treatment of Schizophrenia Negative Symptoms: Future Prospects
Schizophr Bull, April 1, 2006; 32(2): 234 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
H.-Y. Lane, Y.-C. Chang, Y.-C. Liu, C.-C. Chiu, and G. E. Tsai
Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Study
Arch Gen Psychiatry, November 1, 2005; 62(11): 1196 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. G. Kinney, C. Sur, M. Burno, P. J. Mallorga, J. B. Williams, D. J. Figueroa, M. Wittmann, W. Lemaire, and P. J. Conn
The Glycine Transporter Type 1 Inhibitor N-[3-(4'-Fluorophenyl)-3-(4'-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior
J. Neurosci., August 20, 2003; 23(20): 7586 - 7591.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. G. Kinney, M. Burno, U. C. Campbell, L. M. Hernandez, D. Rodriguez, L. J. Bristow, and P. J. Conn
Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 116 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Chumakov, M. Blumenfeld, O. Guerassimenko, L. Cavarec, M. Palicio, H. Abderrahim, L. Bougueleret, C. Barry, H. Tanaka, P. La Rosa, et al.
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia
PNAS, October 15, 2002; 99(21): 13675 - 13680.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. C. Goff and J. T. Coyle
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Am J Psychiatry, September 1, 2001; 158(9): 1367 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. M. Dursun and J. F. W. Deakin
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study
J Psychopharmacol, July 1, 2001; 15(4): 297 - 301.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
H. M. Ibrahim, A. J. Hogg Jr., D. J. Healy, V. Haroutunian, K. L. Davis, and J. H. Meador-Woodruff
Ionotropic Glutamate Receptor Binding and Subunit mRNA Expression in Thalamic Nuclei in Schizophrenia
Am J Psychiatry, November 1, 2000; 157(11): 1811 - 1823.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
A. Kopelowicz, R. Zarate, K. Tripodis, V. Gonzalez, and J. Mintz
Differential Efficacy of Olanzapine for Deficit and Nondeficit Negative Symptoms in Schizophrenia
Am J Psychiatry, June 1, 2000; 157(6): 987 - 993.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. A. Johnson, N. T. Luu, T. A. Herbst, R. Knapp, D. Lutz, A. Arai, G. A. Rogers, and G. Lynch
Synergistic Interactions between Ampakines and Antipsychotic Drugs
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 392 - 397.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
W. T. Carpenter Jr., R. W. Buchanan, B. Kirkpatrick, and A. F. Breier
Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia
Am J Psychiatry, February 1, 1999; 156(2): 299 - 303.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
S. G. Potkin, Y. Jin, B. G. Bunney, J. Costa, and B. Gulasekaram
Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant Schizophrenia
Am J Psychiatry, January 1, 1999; 156(1): 145 - 147.
[Abstract] [Full Text]

Home page
 Arch Gen PsychiatryHome page
D. C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D. A. Schoenfeld, D. L. Hayden, R. McCarley, and J. T. Coyle
A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia
Arch Gen Psychiatry, January 1, 1999; 56(1): 21 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
U. Heresco-Levy, D. C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Arch Gen Psychiatry, January 1, 1999; 56(1): 29 - 36.
[Abstract] [Full Text] [PDF]

Home page
 JPEN J Parenter Enteral NutrHome page
J. C. Hall
Review: Glycine
JPEN J Parenter Enteral Nutr, November 1, 1998; 22(6): 393 - 398.
[Abstract] [PDF]